Cellular Biomedicine Group, Inc. today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell therapy for Knee Osteoarthritis , which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.
http://www.freshnews.com/news/840540/cellular-biomedicine-group-announces-positive-interim-results-phase-i-iia-clinical-tria
http://www.freshnews.com/news/840540/cellular-biomedicine-group-announces-positive-interim-results-phase-i-iia-clinical-tria
No comments:
Post a Comment